Virna Borowski - Concepedia

Author

Virna Borowski

Bristol-Myers Squibb (United States)

Also Known As

Borowski, Virna, V BOROWSKI, V. BOROWSKI, V. Borowski, Virna B. Borowski, Virna Borowski

Publications

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Enzon Pharmaceuticals (United States)Bristol-Myers Squibb (India)Biocon (India)Johnson & Johnson (United States)

About

Virna Borowski is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	567
2	Biochemistry	4	4	192
3	Natural Sciences	2	2	331
4	Engineering	1	1	118
5	Allergy	1	1	67

Virna Borowski

Publications

993

Citations

H-Index

Page 1

	Year	Citations
Structure−Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation Amartya Basu, Karen Yang, Maoliang Wang, Bioconjugate Chemistry Ethylene GlycolImmunologyStructure−function EngineeringBiological TherapyTherapeutics	2006	213
Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation Kaiyong Yang, Anirban Basu, Ramesh Chintala, Protein Engineering Design and Selection EngineeringProtein AssemblyPeptide EngineeringImmunologyMolecular Biology	2003	118
Antitumor activity of poly(ethylene glycol)–camptothecin conjugate: The inhibition of tumor growth in vivo Deshan Yu, Ping Peng, S. Dharap, Journal of Controlled Release Tumor BiologyEthylene GlycolOncologyAntitumor ActivityPolymer-drug Conjugate	2005	116
Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C.II. Efficacy in ascites and solid tumors Yun H. Choe, Cheryl A. Conover, Dee Wu, Journal of Controlled Release NanomedicineEthylene GlycolDrug TargetingOncologySolid Tumors	2002	77
Engineering of a Novel Anti-CD40L Domain Antibody for Treatment of Autoimmune Diseases Jenny Xie, Aaron P. Yamniuk, Virna Borowski, The Journal of Immunology ImmunologyImmune RegulationImmunologic MechanismAntigen ProcessingCd4 T Cell Responses	2014	67
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor Jennifer A. Seamon, Catherine A. Rugg, Stuart L. Emanuel, Molecular Cancer Therapeutics	2006	57
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse Agonists James J.‐W. Duan, Zhonghui Lu, Bin Jiang, ACS Medicinal Chemistry Letters	2019	52
Discovery of BMS-986251: A Clinically Viable, Potent, and Selective RORγt Inverse Agonist Robert J. Cherney, Lyndon A. M. Cornelius, Anurag Srivastava, ACS Medicinal Chemistry Letters	2020	41
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity Hua Gong, David S. Weinstein, Zhonghui Lu, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyPregnane X ReceptorBiochemistryFunctional SelectivityMedicine	2017	38
Rationally Designed, Conformationally Constrained Inverse Agonists of RORγt—Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy David Marcoux, James J.‐W. Duan, Qing Shi, Journal of Medicinal Chemistry	2019	37

Page 1